小剂量长春瑞滨口服治疗难治性晚期肿瘤的疗效分析

Efficacy of low-dose vinorelbine tartrate capsules for refractory advanced tumor

目的:探讨小剂量长春瑞滨口服治疗多线化疗后难治性晚期肿瘤的临床效果及毒副反应。方法:对2006年6月至2013年5月期间收治的10例多线化疗后难治性晚期肿瘤患者予单药或联合口服小剂量长春瑞滨软胶囊化疗直至疾病进展,观察疗效和不良反应,并进行生存随访。结果:10例患者经口服长春瑞滨软胶囊后6例患者病情稳定,4例患者病情进展,疾病控制率达60%。10例患者无进展生存期(progression free survival,PFS)为3-64个月,中位PFS为8个月,其中6例病情稳定患者PFS为8-64个月,中位PFS为8个月。最常见的不良反应为腹泻和白细胞下降,10例患者中有1例II度腹泻,1例II度白细胞下降,其余不良反应均为I度,均耐受良好。结论:小剂量长春瑞滨软胶囊在治疗多线化疗后难治性晚期肿瘤患者中显示出一定的疗效,不良反应小,值得进一步扩大样本进行验证。

Objective： To study the efficacy and safety of low- dose vinorelbine tartrate capsules for refractory advanced tumor after multi- lines chemotherapy. Methods： Clinical data of ten refractory advanced tumor patients between June 2006 to May 2013,the curative and adverse effects were evaluated. Results： Six of the ten patients had stable disease and four of the ten patients had progressive disease. The PFS of the ten patients was 3- 64 months and the median PFS was eight months. The PFS of the six patients who had stable disease was 8- 64 months and the median PFS was eight months. One patient developed grade II neutropenia and one patient developed grade II diarrhoea. The rest were well tolerated. Conclusion： Low- dose vinorelbine tartrate capsules has curative effects,and its adverse effects are tolerable. Further research with a larger sample size is needed.